A
Price
$129.81
Change
+$0.26 (+0.20%)
Updated
Jun 12, 04:59 PM (EDT)
Capitalization
36.67B
67 days until earnings call
Intraday BUY SELL Signals
AVXL
Price
$2.51
Change
+$0.01 (+0.40%)
Updated
Jun 12, 04:59 PM (EDT)
Capitalization
232.61M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

A vs AVXL

Header iconA vs AVXL Comparison
Open Charts A vs AVXLBanner chart's image
A vs AVXL Comparison Chart in %
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7.84B. The market cap for tickers in the group ranges from 658 to 191.7B. AMGN holds the highest valuation in this group at 191.7B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 1%. For the same Theme, the average monthly price growth was 277%, and the average quarterly price growth was 5,933%. OTLK experienced the highest price growth at 40%, while CYPH experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -3%. For the same stocks of the Theme, the average monthly volume growth was -0% and the average quarterly volume growth was -6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 69
Price Growth Rating: 57
SMR Rating: 85
Profit Risk Rating: 88
Seasonality Score: 22 (-100 ... +100)

Market Cap

The average market capitalization across the group is 18.41B. The market cap for tickers in the group ranges from 231.68M to 36.59B. A holds the highest valuation in this group at 36.59B. The lowest valued company is AVXL at 231.68M.

High and low price notable news

The average weekly price growth across all stocks in the group was -9%. For the same group, the average monthly price growth was -2%, and the average quarterly price growth was -22%. A experienced the highest price growth at -6%, while AVXL experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the group was -2%. For the same stocks of the group, the average monthly volume growth was -1% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 13
P/E Growth Rating: 82
Price Growth Rating: 67
SMR Rating: 71
Profit Risk Rating: 97
Seasonality Score: 67 (-100 ... +100)
VS
A vs. AVXL commentary
Jun 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and AVXL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2026
Stock price -- (A: $129.55 vs. AVXL: $2.50)
Brand notoriety: A and AVXL are both not notable
A represents the Medical Specialties, while AVXL is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: A: 87% vs. AVXL: 93%
Market capitalization -- A: $36.67B vs. AVXL: $232.61M
A [@Medical Specialties] is valued at $36.67B. AVXL’s [@Biotechnology] market capitalization is $232.61M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $112.92B to $0. The average market capitalization across the [@Medical Specialties] industry is $15.16B. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileAVXL’s FA Score has 1 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • AVXL’s FA Score: 1 green, 4 red.
According to our system of comparison, A is a better buy in the long-term than AVXL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 4 TA indicator(s) are bullish while AVXL’s TA Score has 4 bullish TA indicator(s).

  • A’s TA Score: 4 bullish, 6 bearish.
  • AVXL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AVXL is a better buy in the short-term than A.

Price Growth

A (@Medical Specialties) experienced а -6.37% price change this week, while AVXL (@Biotechnology) price change was -11.35% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.37%. For the same industry, the average monthly price growth was +8.38%, and the average quarterly price growth was -4.28%.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.85%. For the same industry, the average monthly price growth was +90.93%, and the average quarterly price growth was +2061.33%.

Reported Earning Dates

A is expected to report earnings on Aug 18, 2026.

AVXL is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Medical Specialties (-0.37% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Biotechnology (+0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($36.7B) has a higher market cap than AVXL($233M). A YTD gains are higher at: -4.404 vs. AVXL (-29.775). A has higher annual earnings (EBITDA): 1.96B vs. AVXL (-39.58M). A has more cash in the bank: 1.81B vs. AVXL (132M). AVXL has less debt than A: AVXL (88.2K) vs A (3.36B). A has higher revenues than AVXL: A (7.23B) vs AVXL (0).
AAVXLA / AVXL
Capitalization36.7B233M15,751%
EBITDA1.96B-39.58M-4,957%
Gain YTD-4.404-29.77515%
P/E Ratio26.07N/A-
Revenue7.23B0-
Total Cash1.81B132M1,369%
Total Debt3.36B88.2K3,803,855%
FUNDAMENTALS RATINGS
A vs AVXL: Fundamental Ratings
A
AVXL
OUTLOOK RATING
1..100
3761
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
4498
PRICE GROWTH RATING
1..100
4391
P/E GROWTH RATING
1..100
64100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (6) in the Biotechnology industry is in the same range as AVXL (20). This means that A’s stock grew similarly to AVXL’s over the last 12 months.

A's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as AVXL (100). This means that A’s stock grew similarly to AVXL’s over the last 12 months.

A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for AVXL (98). This means that A’s stock grew somewhat faster than AVXL’s over the last 12 months.

A's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for AVXL (91). This means that A’s stock grew somewhat faster than AVXL’s over the last 12 months.

A's P/E Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for AVXL (100). This means that A’s stock grew somewhat faster than AVXL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AAVXL
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
60%
Bullish Trend 15 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
A
Daily Signal:
Gain/Loss:
AVXL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KMKAX78.69N/A
N/A
Kinetics Market Opportunities Adv A
FMAMX98.75N/A
N/A
Fidelity Advisor Stock Sel A
RPXIX28.42N/A
N/A
RiverPark Large Growth Institutional
FHLFX15.98N/A
N/A
Fidelity Series International Index
FPKFX18.28N/A
N/A
Fidelity Puritan K6

A and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To A
1D Price
Change %
A100%
-1.57%
TMO - A
74%
Closely correlated
-1.32%
BRKR - A
72%
Closely correlated
+0.47%
WAT - A
71%
Closely correlated
-0.95%
MTD - A
71%
Closely correlated
+0.73%
DHR - A
69%
Closely correlated
-1.55%
More

AVXL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with TENX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
+1.63%
TENX - AVXL
47%
Loosely correlated
+2.04%
AXON - AVXL
45%
Loosely correlated
-0.31%
VCYT - AVXL
41%
Loosely correlated
-1.56%
ARRY - AVXL
41%
Loosely correlated
+9.00%
MAZE - AVXL
37%
Loosely correlated
+1.82%
More